Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death
May 04, 2021 07:30 ET
|
Progenity, Inc.
Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially...
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
April 30, 2021 16:04 ET
|
Progenity, Inc.
SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Two Abstracts for Novel Ingestible Drug Delivery Technologies at Digestive Disease Week 2021
April 26, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
April 08, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies
April 06, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
March 18, 2021 16:05 ET
|
Progenity, Inc.
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M...
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 12, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces $25 Million Private Placement
February 23, 2021 07:45 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
February 17, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
February 12, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...